PMID- 31088409
OWN - NLM
STAT- In-Process
LR  - 20190522
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 19
IP  - 1
DP  - 2019 May 14
TI  - High expression of MMP19 is associated with poor prognosis in patients with
      colorectal cancer.
PG  - 448
LID - 10.1186/s12885-019-5673-6 [doi]
AB  - BACKGROUND: Matrix metalloproteinase 19 (MMP19) is a member of zinc-dependent
      endopeptidases, which have been involved in various physiological and
      pathological processes. Its expression has been demonstrated in some types of
      cancers, but the clinical significance of MMP19 in colorectal cancer (CRC) has
      not been reported. Thus, we aimed to analyze the clinical significance of MMP19
      in CRC in present study. METHODS: The expression of MMP19 was first explored in
      The Cancer Genome Atlas (TCGA) cohort, and then validated in the GSE39582 cohort 
      and our own database. Clinicopathological features and survival rate were also
      investigated. RESULTS: MMP19 was found to be a predictor for overall survival
      (OS) in both univariate (hazard ratio [HR]: 1.449, 95% confidence interval [CI]: 
      1.108-1.893, P = 0.007) and multivariate survival analyses (HR: 1.401, 95% CI:
      1.036-1.894, P = 0.028) in the TCGA database. MMP19 was further validated as an
      independent factor for recurrence free survival in the GSE39582 database by both 
      univariate analysis (HR: 2.061, 95%CI: 1.454-2.921, P < 0.001) and multivariate
      analysis (HR = 1.470, 95% CI: 1.025-2.215, P = 0.032). In an in-house cohort,
      MMP19 was significantly upregulated in CRC tissues when compared with their
      adjacent normal controls (P < 0.001). Ectopic MMP19 expression was positively
      associated with lymph node metastases (P = 0.029), intramural vascular invasion
      (P = 0.015) and serum carcinoembryonic antigen levels (P = 0.045). High MMP19
      expression correlated with a shorter OS (HR = 5.595; 95% CI: 2.573-12.164; P <
      0.001) and disease free survival (HR = 4.699; 95% CI: 2.461-8.974; P < 0.001) in 
      multivariate cox regression analysis. CONCLUSIONS: Expression of MMP19 was
      upregulated in CRC. High expression of MMP19 was determined to be an independent 
      and poor prognostic factor in CRC. These results suggest that MMP19 may be a good
      biomarker for CRC.
FAU - Chen, Zaiping
AU  - Chen Z
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Wu, Guiyang
AU  - Wu G
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Ye, Fubo
AU  - Ye F
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Chen, Guoping
AU  - Chen G
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Fan, Qinghao
AU  - Fan Q
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Dong, Hao
AU  - Dong H
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
FAU - Zhu, Xiongwen
AU  - Zhu X
AUID- ORCID: http://orcid.org/0000-0001-8950-4720
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China.
      zxw13906578255@163.com.
FAU - Wu, Chongshan
AU  - Wu C
AD  - Department of General Surgery, Taizhou Municipal Hospital, Medical College of
      Taizhou University, Taizhou, 318000, Zhejiang Province, China. joey.woo@163.com.
LA  - eng
PT  - Journal Article
DEP - 20190514
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
PMC - PMC6518766
OTO - NOTNLM
OT  - Colorectal cancer
OT  - MMP19
OT  - Survival analysis
EDAT- 2019/05/16 06:00
MHDA- 2019/05/16 06:00
CRDT- 2019/05/16 06:00
PHST- 2018/10/13 00:00 [received]
PHST- 2019/05/03 00:00 [accepted]
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2019/05/16 06:00 [medline]
AID - 10.1186/s12885-019-5673-6 [doi]
AID - 10.1186/s12885-019-5673-6 [pii]
PST - epublish
SO  - BMC Cancer. 2019 May 14;19(1):448. doi: 10.1186/s12885-019-5673-6.